Source: Marketscreener

Elevar Therapeutics: Relay Therapeutics Signs Global Licensing Deal With Elevar Therapeutics for Lirafugratinib

Read full article »
Elevar Therapeutics's Competitors | Elevar Therapeutics's News | Elevar Therapeutics's Financials
Stay up-to-date with the latest news on Elevar Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Kate Flavin McKinley's photo - CEO of Elevar Therapeutics

CEO

Kate Flavin McKinley

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Elevar Therapeutics